The Price (or Lack) of Global Health

Posted by Ed Schoonveld on Fri, Dec 20, 2019

Governments, private health insurers and employers worldwide are deeply concerned about the increasing cost of healthcare. U.S. healthcare cost as a share of GDP has nearly tripled from 1970 to 2017, resulting in a growing societal burden.


>
Read More

Global Prescription Drug Costs: Why We Need Differential Pricing

Posted by Ed Schoonveld on Wed, Dec 18, 2019

The Trump administration is not the first government to explore the use of international price referencing to force drug prices down. This usually involves the institution of a price ceiling based on an average price for the same drug in a “basket” of other countries. The basket is supposed to consist of countries with similar income levels, but oftentimes that’s not actually the case. That’s just one of the many problems with international price referencing laws.


>
Read More

Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Dec 16, 2019

Dean Hakanson co-wrote this blog post with Ed Schoonveld.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

The 2019 STAT Summit: ‘You Don’t Burn the House Down to Get Rid of Rats’

Posted by Ed Schoonveld on Tue, Nov 26, 2019

Many senior leaders in the healthcare and pharmaceutical space gathered at the inaugural STAT Summit on Nov. 21st at the MIT campus in Cambridge, Mass. The invitation-only summit featured an interesting mix of exciting medical scientific advances, including bionic limbs, artificial intelligence, the impact of real-world evidence on drug development, and patient testimonials regarding some great medical and pharmaceutical innovations.


>
Read More

Global Fair Pricing Tensions

Posted by Ed Schoonveld on Thu, May 16, 2019

Pricing for prescription drugs has been a contentious issue around the world as payers and patients don’t understand the cause of high drug prices and are struggling with patient access. Particularly in middle- and low-income countries, affordability of drugs in cancer has become an important part of a dialogue between the World Health Organization, governments, non-governmental organizations and patient advocates. The WHO has organized several meetings to explore and drive resolutions for drug-pricing-related issues for patented and generic drugs.


>
Read More